• Japanese
  • Korean
  • Chinese
Cover Image

Osteoporosis Therapeutics

Abstract

This report analyzes the worldwide markets for Osteoporosis Therapeutics in US$ Million by the following major therapeutic classes: Bisphosphonates, ERT Drugs, SERMs, Calcitonins, and MAB (Denosumab). The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 49 companies including many key and niche players such as Abbott Laboratories, Eli Lilly and Company, F.Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer, Inc., Wyeth, Sanofi-Aventis SA, Servier SA, Unigene Laboratories, Inc., and Warner Chilcott plc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc. (GIA) is a reputed publisher of off-the-shelf market research. Recognized as one of the most consistently accurate forecasting company in the world, GIA currently serves more than 9,500 companies from 36 countries worldwide. The company was founded in 1987, initially recognized globally as a research boutique specializing in the medical industry. Over the past 25 years, the company expanded its coverage and now publishes extensively upon more than 180 major industries.

Our experienced team is dedicated to world-class research and analysis. We attribute our success to our people, their commitment and work culture.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Bisphosphonates
    • Hormone Replacement Therapy/Estrogen Replacement Therapy
      • Estrogens
      • Estrogens/Progesterones
    • Calcitonins
    • Selective Estrogen Receptor Modulators (SERMs)
    • Other Therapeutics

II. EXECUTIVE SUMMARY

1. OUTLOOK

  • Generic Incursion Drubs Market Revenues Worldwide
  • Novel Therapies to Recuperate Market Growth
  • Denosumab Bodes Significant Market Opportunities

2. MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE

  • Bisphosphonates
  • The leading Therapeutic Market - Only for Now
  • ERT Drugs
  • Ups and Downs in the ERT Market
  • SERMs (Selective Estrogen Receptor Modulators)
  • Market Overview
  • Calcitonins
  • Market Overview
  • Monoclonal Antibodies (Denosumab)
  • Market Overview
  • New Drugs/Drug Classes in Pipeline
  • End-Stage Therapies (Under Development) for Osteoporosis Prevention/Cure
  • SERMs
    • Eli Lilly Drops Clinical Study of Arzoxifene for Bone Loss
    • Pfizer Intends to Withdraw NDAs for Fablyn
  • Bisphosphonates
    • Zoledronic Acid
    • Pamidronate
  • Calcitonin
    • Emisphere's Oral Calcitonin Candidate Fails to Clear Clinical Trials
  • Parathyroid Hormone (PTH)
    • Novartis Terminates Clinical Study of Oral Formulation of PTH1-34
  • Monoclonal Antibodies - Denosumab
    • Table 1: Comparison of Major Osteoporosis Drugs in Reducing Risk of Fracture
    • RANK Ligand
  • Combination Therapy
  • Others
    • Cathepsin K inhibitors
      • Merck Releases New Data for Odanacatib

3. MARKET DYNAMICS

  • Facts & Figures: The Osteoporosis Primacy
  • Snapshots
    • Table 2: Prevalence of Osteoporosis and Osteopenia in Major Markets including US, Germany, Italy, France, UK, Spain and Japan: 2003-2013 (In Millions) (includes corresponding Graph/Chart)
  • Osteoporosis Therapeutics: An Evolutionary Scan
  • Currently Available Drugs for Osteoporosis Treatment
  • "A Sketch of the Present Industry Scenario"
  • Factors Influencing Demand
  • Altering Competitive Landscape in Osteoporosis Market
    • Table 3: Leading Drugs in the Global Osteoporosis Therapeutics Market (2006-2009): Value Sales for Actonel, Fosamax, Evista, Boniva, Forteo and Aclasta/Reclast in US$ Million (includes corresponding Graph/Chart)
    • Table 4: Leading Osteoporosis Therapies and its Cost per Day
  • Market Trends and Issues
  • Poor Disease Detection - A Major Market Constraint
  • Reluctance to Undergo HRT to Increase Osteoporosis Burden
  • Patent Expiries to Impact Market Growth
  • Limitations Bog Down Current Therapies
  • Growth Opportunities Galore for New Drugs
  • Bisphosphonates to Lose Market Value
  • Poor Compliance Mars Use of Bisphosphonates
  • Side Effects of HRT Fuel Natural Alternatives Sales
  • Bone Formation Drugs Augur New Prospects
    • A Sneak Into Various Options in Antiresorptives, Anabolic Therapeutics
  • Estrogen Replacement Therapy: Will Dosing Make a Difference?
  • Is Prevention Always Better Than Cure?
  • Peptide-Based Osteoporosis Therapy Gaining Ground
  • Polymorphism- A Potent Diagnostic Marker
  • Bisphosphonates - The Other Side
  • Efficacy of Evista under the Scanner

4. PRODUCT OVERVIEW

  • The "Silent Thief"
  • An Introduction to Bone Physiology
  • How Osteoporosis Steps In
  • Osteoporosis: Major Types
  • Primary Osteoporosis
  • Secondary Osteoporosis
  • Osteoporosis - The Aftermath
  • Prevention: The Only Better Way Out
  • Osteoporosis Therapies: A Cursory Glance
  • Non-drug Therapy
  • Drug Therapy
  • Major Osteoporosis Therapeutic Classes: A Brief Review
  • Bisphosphonates
    • Classification of Bisphosphonates
      • Alendronate II-24 Etidronate
      • Risedronate
  • Calcitonins: A Relatively Safer Therapeutic
    • What It Is
    • What It Does
    • Major Types
      • Salmon Calcitonin
  • SERM: A Breakthrough
    • Raloxifene: Most Widely Approved SERM
    • SERMs: The Positive Angle
    • SERMs: The Negative Side
  • Hormone Replacement Therapy/Estrogen Replacement Therapy: The Longstanding Therapeutic
    • ERT: The Positive Side
    • The Negative Angle to ERT
  • Tereparatide: The First Anabolic Agent
    • Composition
    • Forteo: A Leading Brand
      • Major Osteoporosis Therapeutic Classes at a Glance
      • Osteoporosis Therapeutics: A Peek into the Major Brands

5. PRODUCT INTRODUCTIONS/APPROVALS

  • Pfizer Launches Bazedoxifene in Japan
  • Daiichi Files for Approval of Denosumab in Japan
  • Amgen Obtains FDA Approval for Prolia (denosumab) in Treating Post-Menopausal Osteoporosis
  • Amgen Obtains EC Approval for Marketing Prolia(r)
  • Teva to Launch Generic Version of Evista
  • Eli Lilly Obtains FDA Approval for Expanded Indication of Forteo(r)
  • WANBURY Introduces a Calcium Brand, CDENSE, in India
  • Yissum Launches New Compound for Osteoporosis Treatment
  • Novartis Bags US Approval for Reclast
  • Wyeth Obtains EC Approval for Conbriza(tm)
  • Ono and Astellas Introduce Bonoteo in Japan
  • European Commission Grants Approval to Pfizer for FABLYN(r) Tablets

6. PRODUCT INTRODUCTIONS/INNOVATIONS - A HISTORIC PERSPECTIVE BUILDER

  • MDRNA Receives Tentative Approval for New Osteoporosis Drug
  • Novartis Receives EU Approval for Aclasta
  • Sun Pharmaceutical Industries Receives Approval for Fosamax (S)
  • Dr Reddy's Obtains Approval for Production and Marketing of Generic Fosamax
  • Aurobindo Pharma Obtains Approval for Introducing Sodium Tablets in the US
  • Procter & Gamble Obtains Approval for Actonel
  • Eli Lilly Obtains European Commission Approval for FORSTEO(r)
  • Ranbaxy Collaborates with Virchow to Introduce Bonista Teriparatide Injection
  • Barr Pharmaceuticals Subsidiary Introduces Generic Osteoporosis Drug
  • Teva Pharmaceutical Industries Obtains Approval for Generic Fosamax(r) Tablets
  • P&G Receives FDA Approval for New Dosage of Actonel
  • Takeda Introduces Benet(r) for Osteoporosis Treatment
  • Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
  • Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA
  • Merck's New Dosage of FOSAMAX PLUS D Gains FDA Approval
  • Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug
  • Roche and GlaxoSmithKline Introduce Bonviva
  • GlaxoSmithKline and Roche Co-Promoted Boniva Receives FDA Approval
  • Nycomed's Preotact Recommended for Approval in Europe
  • Procter & Gamble and Sanofi-Aventis' Actonel Approved for Male Osteoporosis
  • Upsher-Smith Laboratories Rolls Out Fortical Nasal Spray
  • Teva Receives Tentative FDA Approval for Risedronate Sodium Tablets
  • GlaxoSmithKline and Roche Receive Approval for Bonviva in Switzerland
  • Roche's Once-a-month Bisphosphonate Gets FDA Nod
  • Actonel with Calcium(r) Obtains FDA Approval
  • FDA Approves Unigene's Nasal Calcitonin

7. MAJOR CLINICAL TRIALS/FINDINGS

  • Azelon Pharmaceuticals Completes Phase II trails for Comparing Nasal Spray Formulation of Teriparatide with Forteo, Administered Subcutaneously
  • GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics
  • Radius Initiates Phase II Trials for BA058
  • Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin
  • Medivir Initiates First Human Trials for MIV-701
  • Osteologix Begins Phase II Trial of NB S101
  • Zelos and Nektar Initiates Phase I Clinical Trial of Ostabolin-C(tm)
  • Acceleron Initiates Phase I Clinical Trial of ACE-011
  • Positive Results from Reclast Clinical Trials

8. RECENT INDUSTRY ACTIVITY

  • Sanofi Amends Agreement with Warner Chilcott for Actonel(r)
  • Oramed and Laser Detect Systems Ink Joint Venture Agreement
  • Orchid Chemicals and Pharmaceuticals, and Alvogen Ink Agreement
  • Abbott Takes Over Solvay Pharmaceuticals
  • Novartis Obtains Clearance To Continue Clinical Trials on Oral Calcitonin
  • Merck Merges with Schering-Plough
  • Warner Chilcott Acquires Pharmaceuticals Business of P&G
  • Unigene Laboratories Signs Agreement with Tarsa Therapeutics
  • Bone Medical Obtains Formal Response from FDA for Capsitonin's IND
  • US District Court Confirms Validity of Eli Lilly's Patent for Evista(r)
  • US District Court Confirms Validity of Unigene's Patent for Fortical(r)
  • Ajinomoto Announces Japan Rights for Risedronate Hydrate from P&G
  • Amgen and GSK Join Forces to Market Denosumab
  • Galapagos-Lily Collaboration Achieves Milestone in Osteoporosis Treatment
  • EffRx and Nycomed Sign Licensing Deal for EX101
  • Pfizer Takes Over Wyeth
  • Pfizer Obtains Complete Response Letter from US FDA for Lasofoxifene
  • Wockhardt Signs Agreement with DSM Nutritional for Launch of Bonistein in India

9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER

  • MorphoSys and Galapagos Form Long-Term Development Alliance
  • Daiichi Sankyo Establishes Ireland-Based Subsidiary
  • Merck and Japan Tobacco Sign Global Licensing Agreement for JTT-305
  • Zelos Therapeutics Signs Agreements for Registration Study of ZT-031
  • NuVasive Takes Over Osteocal Biologics Business of Osiris Therapeutics
  • Eli Lilly and TransPharma Medical Sign Licensing and Development Agreement
  • Bone Medical Joins Hands with Hyundai Pharm. for Marketing PTH in South Korea
  • Eli Lilly to Acquire Osteoporosis Drug Patch from TransPharma Medical
  • Wyeth Obtains Approvable Letter from FDA for Bazedoxifene
  • Daiichi Sankyo Establishes Subsidiary in Turkey
  • Aegis Therapeutics and Zelos Therapeutics Sign Agreement for ZT-031
  • Teijin Pharma Obtains a License from Dong Wha Pharm for DW-1350
  • IOF Signs Agreements with Chinese Organizations for Osteoporosis Treatment
  • DAIICHI SANKYO Takes Over EVISTA(r) from Eli Lilly
  • Daiichi Sankyo Acquires Developing and Marketing Rights for Denosumab in Japan
  • Schering-Plough Acquires Organon BioSciences
  • Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline
  • Alethia and Emerillon Collaborate on Osteoporosis Therapies
  • Ipsen Enters into Co-marketing Agreement with MSD
  • Unigene Enters into Agreement with Novartis
  • Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
  • Procter & Gamble Terminates Nasal Spray Collaboration with Nastech Pharmaceutical
  • Pharming Group Acquires DNage
  • Amgen Acquires Abgenix
  • P&G Licenses Osteoporosis Nasal Spray Rights from Nastech
  • Eli Lilly to Close Basingstoke Plant
  • Galapagos Acquires Drug Discovery Platform of Discovery Partners
  • Duravest Acquires Bio-Magnetic Therapy
  • Galapagos Acquires ProStrakan's ProSkelia
  • Roche Inks a Marketing Agreement with Elder Pharma
  • Chugai and Taisho Sign a Joint Development and Marketing Agreement
  • Theragenex Signs a Licensing Agreement with Zylera
  • Radius Acquires Licensing Agreement for Eisai's SERMs
  • Alkermes Partners with Eli Lilly to Develop and Market PTH Formulation
  • Radius Acquires Exclusive Rights to Karo Bio's SARMS
  • Unigene Enters into Agreement with Tzamal Bio
  • Galapagos Acquires Inpharmatica
  • Bio-Rad Acquires Provalis Medical Diagnostics Operations
  • Daiichi Sankyo to Market Evista in Europe
  • Biocon Acquires Nobex
  • Radius and Ipsen Enters into Licensing Agreement
  • Novartis Acquires Hexal AG
  • Nippon Chemiphar Signs Agreement with Velcura Therapeutics
  • Biopotential Capital Acquires Osta Biopharma
  • Dnage Commences DNA Research Programme for Osteoporosis Therapeutics
  • Nastech Initiates Phase I Study of PTH 1-34

10. FOCUS ON SELECT GLOBAL PLAYERS

  • Eli Lilly and Company (US)
  • F.Hoffmann-La Roche Ltd (Switzerland)
  • Merck & Co., Inc. (US)
  • Novartis AG (Switzerland)
  • Pfizer, Inc. (US)
  • Wyeth (US)
  • Sanofi SA (France)
  • Servier SA (France)
  • Unigene Laboratories, Inc. (US)
  • Warner Chilcott plc (Ireland)

11. GLOBAL MARKET PERSPECTIVE

    • Table 5: World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 6: World Historic Review for Osteoporosis Therapeutics by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 7: World 15-Year Perspective for Osteoporosis Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 8: World Recent Past, Current & Future Analysis for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 9: World Historic Review for Bisphosphonates by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 10: World 15-Year Perspective for Bisphosphonates by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 11: World Recent Past, Current & Future Analysis for ERT Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 12: World Historic Review for ERT (Estrogen Replacement Therapy) Drugs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 13: World 15-Year Perspective for ERT (Estrogen Replacement Therapy)Drugs by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 14: World Recent Past, Current & Future Analysis for SERMs by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 15: World Historic Review for SERMs (Selective Estrogen Receptors Modulators) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 16: World 15-Year Perspective for SERMs (Selective Estrogen Receptors Modulators) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 17: World Recent Past, Current & Future Analysis for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 18: World Historic Review for Calcitonins by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 19: World 15-Year Perspective for Calcitonins by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 20: World Recent Past, Current & Future Analysis for MAB (Denosumab) by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for MAB (Denosumab) by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe, and Rest of World Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Industry Overview
    • Osteoporosis in the US: An Insight
      • Osteoporosis - An Underserved Market?
      • Statistical Review
    • Table 22: Osteoporosis Prevalence in Post-Menopause Women (includes corresponding Graph/Chart)
    • Table 23: Number of Osteoporosis Patients Undergoing Osteoporosis Therapies (In Thousands) (includes corresponding Graph/Chart)
    • Osteoporosis Prescription Market
    • Table 24: US Osteoporosis Prescription Market (2004-2006): Percentage Share of Leading Drugs - Fosamax, Actonel, Evista, Boniva, Forteo and Others (includes corresponding Graph/Chart)
    • Competitive Scenario
    • Table 25: Leading Players in the US Osteoporosis Market (2004 - A Historic Review) - Market Share by Value Sales for Merck, Eli Lilly, Procter & Gamble/ Sanofi, and Others (includes corresponding Graph/Chart)
    • Competitive Review by Segment - A Historic Review
      • Bisphosphonates
    • Table 26: Leading Players in the US Bisphosphonates Market (2004) - Market Share by Value Sales for Merck and Procter & Gamble/ Sanofi (includes corresponding Graph/Chart)
    • SERMs
    • Calcitonins
      • Patent Expiry of Major Osteoporosis Drugs
  • B. Market Analytics
    • Table 27: The US Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 28: The US Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and Others Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 29: The US 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins, MAB (Denosumab) and Others Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

2. JAPAN

  • Market Analytics
    • Table 30: Japanese Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab)Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 31: Japanese Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 32: Japanese 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3. EUROPE

  • A. Market Analysis
    • Forteo: The First Anabolic Agent in Europe
    • European Regulatory Restricts HRT
    • Calcitonin Embraces New Label
    • Table 33: European Market for Osteoporosis Therapeutics (2005- A Historic Review): Market Share of Leading Players - Novartis, Merck, Wyeth, Novo Nordisk, Organon, Procter & Gamble, Schering, Solvay and Others (includes corresponding Graph/Chart)
  • B. Market Analytics
    • Table 34: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 35: European Historic Review for Osteoporosis Therapeutics by Geographic Region - France, Germany, The UK, Italy, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 36: European 15-Year Perspective for Osteoporosis Therapeutics by Geographic Regions - Percentage Breakdown of Dollar Sales for France, Germany, The UK, Italy, Spain, and Rest of Europe Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 37: European Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 38: European Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 39: European 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3a. FRANCE

  • Market Analytics
    • Table 40: French Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 41: French Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 42: French 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3b. GERMANY

  • Market Analytics
    • Table 43: German Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 44: German Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 45: German 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3c. ITALY

  • Market Analytics
    • Table 46: Italian Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 47: Italian Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 48: Italian 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3d. THE UNITED KINGDOM

  • A. Market Analysis
    • Table 49: Osteoporosis Population in the UK: 2004-2009
  • B. Market Analytics
    • Table 50: The UK Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 51: The UK Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 52: The UK 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3e. SPAIN

  • Market Analytics
    • Table 53: Spanish Recent Past, Current & Future Market Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 54: Spanish Historic Review for Osteoporosis Therapeutics by Product Group - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 55: Spanish 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

3f. REST OF EUROPE

  • A. Market Analysis
    • Romania
  • B. Market Analytics
    • Table 56: Rest of Europe Recent Past, Current & Future Analysis for Osteoporosis by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 57: Rest of Europe Historic Review for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 58: Rest of Europe 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. REST OF WORLD

  • A. Market Analysis
    • Prevalence of Osteoporosis in Various Region - At a Glance
    • Korea
    • Table 59: Korean Osteoporosis Therapeutics Market by Leading Brands (2005 - A Historic Review): Percentage Share Breakdown by Dollar Sales for Fosamax, Atonel, Alend, Maxmarvil, and Others (includes corresponding Graph/Chart)
    • China
  • B. Market Analytics
    • Table 60: Rest of World Recent Past, Current & Future Analysis for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 61: Rest of World Historic Review for Osteoporosis Therapeutics by Product Groups - Bisphosphonates, ERT Drugs, SERMs, and Calcitonins Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 62: Rest of World 15-Year Perspective for Osteoporosis Therapeutics by Product Group - Percentage Breakdown of Dollar Sales for Bisphosphonates, ERT Drugs, SERMs, Calcitonins and MAB (Denosumab) Markets for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Show More
Pricing